Ovarian tissue oocyte-in vitro maturation combined with ovarian tissue cryopreservation: a promising urgent fertility preservation strategy for hematological patients before HSCT Authors: Yingqiao Ding, Tiantian Su, Yanling Wan, Yanru Hou, Yuan Fan, Fang Fang, Peng Zuo, Xiaowei Li, Shengnan Duan, Nannan Huang, Jianliu Wang, Lanping Xu, Rong Liang, Li Tian Published: 2026 ABSTRACT BackgroundHematological diseases to be treated with HSCT are a definite indication for fertility preservation (FP). Ovarian tissue oocyte in vitro maturation (OTO-IVM) combined with ovarian tissue cryopreservation (OTC) may be a promising and urgent FP strategy for this population. This study aims to evaluate the efficacy of OTO-IVM for this population and identify which hematological diseases are more likely to benefit from OTO-IVM.MethodsThis study included 44 hematological patients before HSCT who underwent the OTO-IVM combined with OTC for urgent FP. Patients were divided into the malignant hematological disease (MHD) and non-MHD groups and the OTO-IVM outcomes were retrospectively analysed. Donated ovarian tissues from MHD, non-MHD and control group were subjected to further molecular and pathological study.ResultsPatients with non-MHD exhibited significantly higher serum anti-Müllerian hormone (AMH) levels (4.36 ± 3.14 vs. 2.08 ± 1.57, p = 0.017) and a greater number of retrieved immature oocytes (10.58 ± 7.54 vs. 4.85 ± 3.26, p = 0.012) than those with MHD. Although the maturation rate showed a non-significant decreasing trend in the non-MHD group (35.80 ± 28.12 vs. 49.83 ± 33.96, p = 0.163), multivariable analysis demonstrated that non-MHD was associated with a lower per-patient IVM rate. The final number of MII oocytes did not differ significantly between groups (3.58 ± 4.07 vs. 2.23 ± 2.01, p = 0.264). Notably, increased apoptosis of ovarian stromal cells may contribute to impaired oocyte maturation competence in patients with aplastic anemia (AA). Consistently, AA ovarian tissues displayed activation of apoptotic signalling pathways and dysregulated T cell activation-associated gene expression compared with MHD and impaired oocyte development and maturation compared with control group.ConclusionsOTO-IVM combined with OTC appears feasible for urgent fertility preservation in hematological patients prior to HSCT. Our exploratory findings suggest that ovarian stromal cell apoptosis may contribute to reduced oocyte maturation competence in AA, which warrants further validation and optimization of maturation rates.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13048-026-02136-4. Introduction Hematopoietic stem cell transplantation (HSCT) is a widely used effective treatment for various hematological disorders. Among the indications, malignant hematological diseases (MHDs), including leukaemia and lymphoma, and non-malignant hematological disorders (non-MHDs), especially severe aplastic anemia (AA), constitute two distinct recipient populations [1–3]. The estimated annual number of HSCTs has been growing steadily worldwide [2–4], and the reported number in China reached 18,110 in 2021 [4, 5]. 26% of patients with allogenic HSCT are young women under the age of 40 [6]. The long-term prospects for survival after HSCT are excellent, with an estimated 85% 10-year overall survival rate [7]. As survival is no longer the only goal of treatment, improvements in health-related quality of life, especially preserving reproductive function, should be taken seriously [8]. However, 65–84% of HSCT survivors experienced permanent premature ovarian failure (POF) [6, 9, 10], and only 0.6% of females achieve pregnancy after HSCT [11]. In our centre, the overall POF incidence after allogeneic HSCT was 86% (74% in patients under 13 years of age and 94% in patients ≥ 13 years of age) [12]. Therefore, treatment with HSCT is a definite indication for fertility preservation (FP) [13]. Patients with hematological disease prior to HSCT are often faced with a more urgent timeframe to preserve fertility than those with other solid tumors, such as breast cancer and gynaecological tumors [14, 15]. Therefore, conventional oocyte and embryo cryopreservation is limited due to the treatment duration and potential complications of controlled ovarian hyperstimulation (COH). For ovarian tissue cryopreservation (OTC), there is a high risk of malignant cell reimplantation during frozen-thawed ovarian tissue transplantation in patients with MHD [16]. Given these challenges, it is a critical clinical problem to choose the optimal FP strategy to avoid malignant cell reimplantation and maximise reproductive material diversity to increase future fertility potential within such an urgent timeframe, which is usually only one menstrual cycle. Ovarian tissue oocyte in vitro maturation (OTO-IVM) combined with OTC may be a promising urgent FP strategy for hematological patients before HSCT. Although single reproductive material (oocyte/embryo/ovarian tissue) cryopreservation is the most common strategy at present, researchers have recently attempted a diverse combination of multiple FP protocols to obtain ovarian tissues and oocytes/embryos simultaneously in one menstrual cycle [15, 17, 18]. When patients underwent OTC, the cumulus oocyte complexes (COCs) of antral follicles found in laboratory ovarian tissue processing medium and aspirated from ovarian cortex surface follicles are collected for IVM. This is followed by cryopreservation of MII oocytes or further in vitro fertilised embryos, which is referred as OTO-IVM [15, 17, 19]. OTO-IVM can save wasteful COCs to increase potential oocyte yield and avoid the side effects of COH. This approach is also feasible for preadolescent patients whose ovaries are unresponsive to conventional COH. To date, limited studies have attempted OTO-IVM preliminarily in hematological populations, and research data are insufficient. Moreover, it is unknown which hematological diseases are most likely to benefit from OTO-IVM. Our study aims to compare OTO-IVM outcomes between MHD and non-MHD patients to provide specific insights and propose a new idea for clinical FP strategy decision for hematological patients. Materials and methods Patient characteristics This study included forty-four hematological patients who underwent OTC combined with the OTO-IVM procedure before HSCT to preserve fertility between January 2023 and November 2024. A multidisciplinary discussion was conducted before FP, and each patient was given the choice of stand-alone OTC or a combination of OTC and OTO-IVM. We introduced all patients to OTO-IVM, informing them of the advantages of this protocol to increase the diversity of cryopreserved reproductive materials, and the risks of culture failure, resuscitation and fertilisation failure. All included patients voluntarily opted for OTO-IVM and signed informed consent before surgery. Patients were eligible for inclusion if they met the following criteria: (1) had a confirmed diagnosis of hematological disease based on bone marrow examination or pathological assessment; (2) female patients younger than 40 years of age who required urgent FP prior to HSCT; (3) underwent urgent FP using OTC combined with OTO-IVM; (4) provided written informed consent for the fertility preservation procedure and the use of clinical data for research purposes. Exclusion criteria included: (1) patients undergoing FP for non-hematological diseases or for social indications; (2) patients who underwent FP strategies other than the combined OTC and OTO-IVM protocol, such as OTC alone; (3) patients with a history of ovarian surgery or known ovarian diseases that could affect ovarian function. Patients’ clinical information, including age, body mass index (BMI), medical history, and chemotherapy history, was screened from an electronic database review. Patients were divided into postpubertal and prepubertal groups according to menarche status. At the patient’s initial visit to the reproductive centre for fertility counselling, anti-Müllerian hormone (AMH), and antral follicle count (AFC) detected by transvaginal or transrectal ultrasound were measured to assess ovarian function. Ovarian tissue cryopreservation Patients underwent unilateral oophorectomy or bilateral half-oophorectomy with non-energy device resection to eliminate damage to the ovarian cortex. Once the ovarian tissue was harvested, it was placed in a 4 °C incubator and transferred to the laboratory immediately. The medullary portion of the ovary was removed, and the ovarian cortical tissue was processed into 5 × 5 × 1 mm³ to 5 × 10 × 1 mm³ strip segments. Vitrification was used to cryopreserve the ovarian cortex slices based on previously published protocols [20]. During preparation of the cortical strips for cryopreservation, small residual ovarian cortical fragments remained after trimming of the tissue. These residual cortical fragments were used for histological and viability analyses without affecting the clinical cryopreservation procedure. Before cryopreservation, one of these residual cortical fragments was fixed and embedded in paraffin in preparation for hematoxylin pigment staining to verify the presence of primordial follicles and assess malignant cells. A 2 × 2 × 1 mm³ piece of cortical tissue was subjected to calcein-AM staining to determine the number of living follicles. Gonadotropin priming (Gn-priming) was performed in a subset of patients prior to OTC and OTO-IVM. Human menopausal gonadotropin (hMG, Livzon Pharmaceutical Group Inc., China) was administered at a dose of 112.5–150 IU/day for 3–5 days before surgery. The use of trigger drugs was not involved. After gonadotropin priming, patients underwent the same OTC and OTO-IVM protocol as described above. This protocol was adapted from previously reported short-term gonadotropin priming strategies [17, 21]. OTO collection and biphasic IVM The prematuration culture medium (Medium A) was prepared using Medicult IVM medium supplemented with 1 mIU/mL rFSH, 5 ng/mL insulin, 10 nM estradiol, 10 mg/mL human serum albumin (HSA), and 25 nM C-type natriuretic peptide (CNP). The medium was equilibrated overnight at 37 °C in an incubator with 6% CO₂. The excised ovary was visually inspected before ovarian cortical processing. Follicles with a visible diameter ≥ 0.8 cm were aspirated using a 26-gauge needle, and the follicular fluid was examined under a stereomicroscope to identify COCs, which were directly transferred into Medium A immediately. During subsequent ovarian cortical processing, the processing medium used for tissue handling was also examined under stereomicroscope, and additional COCs were collected. The total time for COCs retrieval was limited to within 30 min. All retrieved COCs were cultured in Medium A at 37 °C in an incubator with 6% CO₂ and 5% O₂. Oocytes obtained through follicular aspiration or found in the processing medium were all considered to be ovarian tissue oocytes (OTOs). After 24 h of culture in Medium A, COCs were evaluated, and oocytes that were denuded from granulose cells and had extruded the first polar body were considered mature (MII stage) and cryopreserved. The remaining immature COCs were transferred to a maturation medium (Medium B), consisting of Medicult IVM medium supplemented with 100 mIU/mL rFSH, 5 ng/mL insulin, 10 nM estradiol, and 100 ng/mL recombinant human amphiregulin, and cultured for an additional 24 h under the same incubation conditions. Following this second culture period, oocytes were reassessed for maturation. Oocytes denuded from granulose cells exhibiting first polar body extrusion were cryopreserved. Remaining COCs were further cultured in Medium B for up to an additional 24 h. At the end of culture, all remaining COCs were totally denuded by gentle pipetting and oocytes maturation were assessed. Mature oocytes were cryopreserved, while immature oocytes were discarded [22]. (Fig. 1) Fig. 1OTO-IVM procedure. Oophorectomy was conducted for ovarian tissue cryopreservation. COCs were collected by puncturing antral follicles on the surface of the ovarian cortex and aspirating the follicular fluid with a 26G needle or picking them from the processing plate. Then, the ovarian tissues were cryopreserved by vitrification, and immature oocytes were cultured in biphasic-IVM medium. Finally, the ovarian tissues and mature oocytes were preserved simultaneously. This figure was created using BioRender.com OTO-IVM procedure. Oophorectomy was conducted for ovarian tissue cryopreservation. COCs were collected by puncturing antral follicles on the surface of the ovarian cortex and aspirating the follicular fluid with a 26G needle or picking them from the processing plate. Then, the ovarian tissues were cryopreserved by vitrification, and immature oocytes were cultured in biphasic-IVM medium. Finally, the ovarian tissues and mature oocytes were preserved simultaneously. This figure was created using BioRender.com The primary outcomes were the number of MII oocytes and the IVM rate. The IVM rate was defined as the MII oocyte number/OTO number. Paraffin sections and H&E staining Donated small ovarian fragments from AA (n = 3) and MHD (n = 3) patients were utilised to investigate the molecular and pathological mechanisms for differential OTO-IVM outcomes of two groups. Patients undergoing OTC for gynecologic diseases without prior chemotherapy exposure served as controls, and surplus ovarian tissue fragments were donated for research purposes (n = 5). Fresh tissue samples were fixed in 4% paraformaldehyde at 4 °C for 24 h. After dehydration through a graded alcohol series and clearing in xylene, the samples were embedded in paraffin wax. The paraffin-embedded blocks were sectioned at a thickness of 5 μm via a microtome. The sections were dried in a 37 °C incubator for 2 h, followed by routine haematoxylin and eosin (H&E) staining. The H&E staining procedure was performed as follows: The sections were deparaffinized in xylene and rehydrated through a graded alcohol series. Then, the sections were stained with haematoxylin for 2 min, rinsed under running water, differentiated in 1% acid alcohol, and blued. The sections were subsequently counterstained with eosin for 1 min. After dehydration and clearing, the slides were mounted with neutral balsam. Finally, the morphology of the ovarian tissues and follicles was observed under an optical microscope, and images were captured for recording. TUNEL assay Ovarian tissues were collected and processed into paraffin sections as previously described. Apoptotic cells were detected using the terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay with an In Situ Cell Death Detection Kit (Roche Applied Science, keyGEN BioTECH, KGA7063) according to the manufacturer’s instructions. The sections were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) to visualise the nuclei. The tissue sections were immediately examined under a fluorescence microscope. All images were captured under consistent exposure parameters. The images were quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The percentage of apoptotic cells was calculated as number of TUNEL-positive cells / total number of DAPI-positive cells X 100%. RNA sequencing Ovarian tissues from the AA, MHD, and control groups were thoroughly ground on ice. Total RNA was extracted using TRIzol reagent according to the manufacturer’s protocol. RNA sequencing was conducted on a HiSeq-PE150 platform (Novogene, China). Gene expression quantification was performed using FeatureCounts (v1.5.0-P3), and fragments per kilobase of transcript per million mapped reads (FPKM) values were calculated. The matrix table contains the raw gene counts for each gene and sample. Statistical analysis Continuous data are presented as the mean ± SD or median (interquartile range, IQR). Categorical data are presented as percentages. Categorical data and non-normally distributed continuous data were analysed by Fisher’s exact test or the Mann‒Whitney U test. A linear regression model was used to evaluate the association between disease type and the per-patient OTO-IVM rate. The analyses were performed with the statistical software packages R version 3.4.3 (http://www.R-project.org, The R Foundation). Statistical analyses of TUNEL images were performed using GraphPad Prism (V10.3.1, GraphPad Software, San Diego, CA, USA). Pairwise comparisons between groups were conducted using two-tailed unpaired Student’s t-test. A two-sided significance level of P < 0.05 was considered statistically significant. Results Patient characteristics The basic information of the 44 included patients who underwent OTO-IVM and OTC before HSCT was shown in Table 1. Patients were grouped by non-MHD group (n = 31) and MHD group (n = 13) (Fig. 2). The average age of all patients was 18.95 ± 7.93 years, ranging from 4 to 37 years, and included 11 prepubescent girls. We found that AMH was significantly higher in the non-MHD group than MHD group (p < 0.05), while there was no significant difference in random FSH level or AFC. A total of 92.31% (12/13) of patients with MHD had received chemotherapy before OTC, with a range of 0–6 chemotherapy cycles. The mean duration from the end of the last chemotherapy day to the OTC day was 43.18 ± 18.49 days. The non-MHD group was free from chemotherapy, but their disease history and treatment duration were significantly longer than MHD group (p < 0.05). In addition, five patients were administered Gn-priming before surgery. Table 1Characteristics of hematological patients underwent OTO-IVM combined with OTCTotal patients (n = 44)Non-MHD (n = 31)MHD (n = 13) P Age (years ± SD)18.95 ± 7.9317.81 ± 7.9521.69 ± 7.480.140Range4–377–374–30BMI (kg/m2)20.55 ± 4.9519.99 ± 4.5822.02 ± 5.760.232AMH (ng/mL)3.69 ± 2.954.36 ± 3.142.08 ± 1.57 0.017 FSH (IU/L)5.81 ± 3.765.39 ± 3.446.74 ± 4.380.286AFC14.22 ± 6.8114.85 ± 6.6912.50 ± 7.180.358Medical history (years)0.54 (0.25, 3.42)1.50 (0.33, 5.50)0.33 (0.25, 0.50) 0.024 Gestation1.000 Yes1 (2.27%)1 (3.23%)0 (0.00%) No43 (97.73%)30 (96.77%)13 (100.00%)Prepuberty0.567 Yes11 (25.00%)9 (29.03%)2 (15.38%) No33 (75.00%)22 (70.97%)11 (84.62%)Gn-priming before OTC1.000 Yes5 (11.36%)4 (12.90%)1 (7.69%) No39 (88.64%)27 (87.10%)12 (92.31%)Chemotherapy before OTC < 0.001 Yes12 (27.27%)0 (0.00%)12 (92.31%) No32 (72.73%)31 (100.00%)1 (7.69%)Chemotherapy times//2.42 ± 1.78 Range//0–6Interval between last chemotherapy and OTC (days)//43.18 ± 18.49 Range21–85Non-MHD Non-malignant hematological disease, MHD Malignant hematological disease, BMI Body mass index, AMH Anti-Mullerian Hormone, FSH Follicle stimulating hormone, AFC Antral follicle count, OTC Ovarian tissue cryopreservation, Gn-priming Gonadotropin priming Table 1Characteristics of hematological patients underwent OTO-IVM combined with OTCTotal patients (n = 44)Non-MHD (n = 31)MHD (n = 13) P Age (years ± SD)18.95 ± 7.9317.81 ± 7.9521.69 ± 7.480.140Range4–377–374–30BMI (kg/m2)20.55 ± 4.9519.99 ± 4.5822.02 ± 5.760.232AMH (ng/mL)3.69 ± 2.954.36 ± 3.142.08 ± 1.57 0.017 FSH (IU/L)5.81 ± 3.765.39 ± 3.446.74 ± 4.380.286AFC14.22 ± 6.8114.85 ± 6.6912.50 ± 7.180.358Medical history (years)0.54 (0.25, 3.42)1.50 (0.33, 5.50)0.33 (0.25, 0.50) 0.024 Gestation1.000 Yes1 (2.27%)1 (3.23%)0 (0.00%) No43 (97.73%)30 (96.77%)13 (100.00%)Prepuberty0.567 Yes11 (25.00%)9 (29.03%)2 (15.38%) No33 (75.00%)22 (70.97%)11 (84.62%)Gn-priming before OTC1.000 Yes5 (11.36%)4 (12.90%)1 (7.69%) No39 (88.64%)27 (87.10%)12 (92.31%)Chemotherapy before OTC < 0.001 Yes12 (27.27%)0 (0.00%)12 (92.31%) No32 (72.73%)31 (100.00%)1 (7.69%)Chemotherapy times//2.42 ± 1.78 Range//0–6Interval between last chemotherapy and OTC (days)//43.18 ± 18.49 Range21–85Non-MHD Non-malignant hematological disease, MHD Malignant hematological disease, BMI Body mass index, AMH Anti-Mullerian Hormone, FSH Follicle stimulating hormone, AFC Antral follicle count, OTC Ovarian tissue cryopreservation, Gn-priming Gonadotropin priming Characteristics of hematological patients underwent OTO-IVM combined with OTC Non-MHD Non-malignant hematological disease, MHD Malignant hematological disease, BMI Body mass index, AMH Anti-Mullerian Hormone, FSH Follicle stimulating hormone, AFC Antral follicle count, OTC Ovarian tissue cryopreservation, Gn-priming Gonadotropin priming Fig. 2Flowchart of fertility preservation strategies for hematological patients before HSCT. OTO-IVM, ovarian tissue oocytes in vitro maturation; AA, aplastic anemia; MHD, malignant hematological disease Flowchart of fertility preservation strategies for hematological patients before HSCT. OTO-IVM, ovarian tissue oocytes in vitro maturation; AA, aplastic anemia; MHD, malignant hematological disease MII oocyte yield and IVM rate of OTO-IVM A total of 315 retrieved OTOs underwent the IVM procedure. The mean number of MII oocytes cryopreserved was 3.18 per patient, and the mean IVM rate per patient was 39.95% (Table 2). Table 2Outcomes of OTO-IVM in hematological patientsTotal patients (n = 44)Non-MHD (n = 31)MHD (n = 13) P Total number of OTO31525263/OTO number per patient8.89 ± 7.0510.58 ± 7.544.85 ± 3.26 0.012 MII oocyte number per patient3.18 ± 3.623.58 ± 4.072.23 ± 2.010.264IVM rate per patient (%)39.95 ± 30.2635.80 ± 28.1249.83 ± 33.960.163Total oocytes matured within 48 h50446/Total oocytes matured after 48 h815823/Living follicles count /mm36.88 (2.75, 15.51)7.62 (3.50, 23.75)6.00 (1.67, 10.00)0.363Available MII oocyte number0.482 0–531 (70.45%)22 (70.97%)9 (69.23%) 6–108 (18.18%)6 (19.35%)2 (15.38%) >102 (4.55%)2 (6.45%)0 (0.00%)Non-MHD Non-malignant hematological disease, MHD Malignant hematological disease, OTO Ovarian tissue oocyte, IVM In vitro maturation Table 2Outcomes of OTO-IVM in hematological patientsTotal patients (n = 44)Non-MHD (n = 31)MHD (n = 13) P Total number of OTO31525263/OTO number per patient8.89 ± 7.0510.58 ± 7.544.85 ± 3.26 0.012 MII oocyte number per patient3.18 ± 3.623.58 ± 4.072.23 ± 2.010.264IVM rate per patient (%)39.95 ± 30.2635.80 ± 28.1249.83 ± 33.960.163Total oocytes matured within 48 h50446/Total oocytes matured after 48 h815823/Living follicles count /mm36.88 (2.75, 15.51)7.62 (3.50, 23.75)6.00 (1.67, 10.00)0.363Available MII oocyte number0.482 0–531 (70.45%)22 (70.97%)9 (69.23%) 6–108 (18.18%)6 (19.35%)2 (15.38%) >102 (4.55%)2 (6.45%)0 (0.00%)Non-MHD Non-malignant hematological disease, MHD Malignant hematological disease, OTO Ovarian tissue oocyte, IVM In vitro maturation Outcomes of OTO-IVM in hematological patients Non-MHD Non-malignant hematological disease, MHD Malignant hematological disease, OTO Ovarian tissue oocyte, IVM In vitro maturation Compared with the MHD group, the number of OTOs per patient was significantly higher in the non-MHD group (10.58 ± 7.54 vs. 4.85 ± 3.26, P = 0.012). Surprisingly, the IVM rate in the non-MHD group was 35.80 ± 28.12%, which was even lower than that in the MHD group (49.83 ± 33.96%). However, there was no significant difference in the number of MII oocytes between the two groups. Two patients in non-MHD groups ultimately cryopreserved more than 10 MII oocytes. Additionally, more than half of the OTOs needed more than 48 h to reach the MII stage (Table 2). Detailed information on the five patients who underwent Gn-priming before OTC is presented in Table S1. The outcomes showed notable heterogeneity. Three patients with AA demonstrated relatively favorable IVM rates (48.7%, 54.5%, and 100%), whereas the other two patients had relatively low IVM rates. Given the small sample size and variability in outcomes, the effect of Gn-priming could not be reliably evaluated. And Gn-priming was additionally adjusted for in the multivariable regression analyses. After adjusting for potential confounders, including age, medical history, and Gn-priming, MHD was independently associated with a higher per-patient OTO-IVM rate compared with non-MHD patients (β = 25.06, 95% CI 2.48–47.64, P = 0.036) (Table S2). Further exploratory stratified analysis by pubertal status showed that, although the association did not reach statistical significance after adjustment for medical history duration and Gn-priming, a consistent trend toward a higher per-patient OTO-IVM rate was observed in the MHD group compared with the non-MHD group in both prepubertal and postpubertal patients (Table S3). Increased apoptosis of stromal cells in the ovarian tissue of AA patients Histological examination of ovarian tissue sections stained with H&E revealed normal follicular morphology across the three groups (Figure S1). To further explore the reasons for the unsatisfactory IVM rate in AA patients, we conducted TUNEL staining on the ovarian tissues of patients with AA, MHD and gynaecological disease. TUNEL staining revealed that the apoptotic ovarian stromal cells in the AA group were significantly higher than in the other groups (Fig. 3). Fig. 3TUNEL staining of ovarian tissues from Ctrl, AA and MHD patients. It revelled increased apoptosis of stromal cells in AA group. Red fluorescence: TUNEL-positive nuclei; blue fluorescence: DAPI. Scale bars: 10 μm TUNEL staining of ovarian tissues from Ctrl, AA and MHD patients. It revelled increased apoptosis of stromal cells in AA group. Red fluorescence: TUNEL-positive nuclei; blue fluorescence: DAPI. Scale bars: 10 μm Dysregulated T-cell activation signalling, enhanced apoptotic pathways, and impaired oocyte development in the ovarian tissues of patients with AA To further investigate the molecular mechanism of the increased apoptosis of ovarian stromal cells in AA patients compared with MHD patients, we performed RNA-sequence analysis (Fig. 4A-F) of ovarian tissues from AA and MHD patients. The results revealed that 273 genes were downregulated and 448 genes were upregulated (Fig. 4A). Analysis of the genes whose expression changed through the GO database revealed that those genes influenced the P53-mediated apoptotic signalling pathway, inner mitochondrial membrane complex signalling pathway, T-cell activation signalling pathway and immune response signalling pathway (Fig. 4B). The specific genes associated with the P53-mediated apoptotic pathway are shown in Fig. 4C. GSEA also revealed that the apoptosis process was activated in AA ovarian tissues (Fig. 4D). In addition, GSEA revealed that the ATP synthesis signalling pathway was inhibited in AA ovarian tissues (Fig. 4E). Because abnormal T-cell activation is the predominant pathogenesis of AA, we further analysed and identified genes associated with T-cell activation that are dysregulated in ovarian tissues. In summary, ovarian tissues of AA presented pathological hyperactivation of the apoptotic signalling pathway and dysregulated T-cell activation-associated gene expression compared with the MHD group. Fig. 4RNA sequences of ovarian tissues from the AA, MHD, and control groups. A Volcano plot comparing ovarian tissues from AA and MHD patients. Transcripts whose expression increased or decreased by > 2-fold are highlighted in red or blue, respectively. B Analysis of genes whose expression changed according to the GO database comparing AA and MHD. C Heatmap of genes related to the P53-mediated apoptotic pathway whose expression differed between the AA and MHD groups. D GSEA revealed increased apoptosis in the AA group compared with the MHD group. E GSEA revealed that ATP synthesis signalling pathways were inhibited in AA patients compared with patients with MDH. F Heatmap of genes related to the T-cell activation pathway whose expression differed between the AA and MHD groups. G Volcano plot comparing the ovarian tissues from AA and Ctrl patients. H GO database analysis of genes whose expression changed between the AA and Ctrl groups. I Heatmap of genes whose expression changed in the oocyte maturation pathway between the AA and Ctrl groups. J GSEA revealed activated ovarian vasoconstriction in the AA group compared with the Ctrl group. K GSEA revealed that the ATP synthesis signalling pathway was inhibited in the AA group compared with the Ctrl group. L GSEA revealed that the mitotic process was blocked in the AA group compared with the Ctrl group RNA sequences of ovarian tissues from the AA, MHD, and control groups. A Volcano plot comparing ovarian tissues from AA and MHD patients. Transcripts whose expression increased or decreased by > 2-fold are highlighted in red or blue, respectively. B Analysis of genes whose expression changed according to the GO database comparing AA and MHD. C Heatmap of genes related to the P53-mediated apoptotic pathway whose expression differed between the AA and MHD groups. D GSEA revealed increased apoptosis in the AA group compared with the MHD group. E GSEA revealed that ATP synthesis signalling pathways were inhibited in AA patients compared with patients with MDH. F Heatmap of genes related to the T-cell activation pathway whose expression differed between the AA and MHD groups. G Volcano plot comparing the ovarian tissues from AA and Ctrl patients. H GO database analysis of genes whose expression changed between the AA and Ctrl groups. I Heatmap of genes whose expression changed in the oocyte maturation pathway between the AA and Ctrl groups. J GSEA revealed activated ovarian vasoconstriction in the AA group compared with the Ctrl group. K GSEA revealed that the ATP synthesis signalling pathway was inhibited in the AA group compared with the Ctrl group. L GSEA revealed that the mitotic process was blocked in the AA group compared with the Ctrl group RNA-sequence analysis of ovarian tissues from patients with AA compared with the control group (Fig. 4G-L) revealed that 529 genes were downregulated and 1342 genes were upregulated (Fig. 4G). The GO database was used to analyse these genes. The results revealed that the genes with altered expression affected oocyte development, the collagen trimer signalling pathway and the ATP hydrolysis signalling pathway (Fig. 4H). The changes in oocyte maturation genes are shown in Fig. 4I. GSEA also revealed that ovarian vasoconstriction was activated (Fig. 4J), the ATP synthesis signalling pathway was inhibited (Fig. 4K), and the mitotic process was blocked in patients with AA (Fig. 4L). In summary, compared to the control group, ovarian tissues from patients with AA presented impaired oocyte development and maturation-related signalling pathways. Taken together, these factors may contribute to diminished oocyte development and maturation competence, leading to an unsatisfactory IVM rate through OTO-IVM in patients with AA. Discussion This is the first study to compare the outcomes of OTO-IVM combined with OTC in patients with malignant and non-malignant hematological diseases before HSCT. Both groups obtained additional available oocytes beyond ovarian tissues, using the OTO-IVM technique. These results suggest that OTO-IVM may be a feasible urgent fertility preservation approach for patients undergoing HSCT. OTO-IVM represents a superior fertility preservation option for hematologic patients. In recent years, multiple combined fertility preservation methods have been used to preserve ovarian function, including COH before or immediately after OTC, transvaginal oocyte pick-up for IVM (OPU-IVM) + OTC and OTO-IVM + OTC [15]. A promising number of MII oocytes were obtained by combined FP methods [15, 17–19, 23–25]. Among those methods, OTO-IVM is used not only for postpubertal women but also prepubertal girls, and the risk of HSCT delay caused by COH complications is avoided because high-dose ovulation induction medicine is not involved [19, 24]. Moreover, unlike OPU-IVM, OTO-IVM eliminates the need for transvaginal oocyte retrieval, thereby reducing operational risk and being friendly to women with no sexual history. For these reasons, we employed OTO-IVM + OTC in hematological patients before HSCT. This is consistent with the opinion of Delattre S et al. that there was a preponderance of OTC + OTO-IVM ± COH for patients with hematological disorders [15]. The biphasic IVM system was first introduced in OTO-IVM procedures for hematological patients. The standard IVM system is widely used in current OTO-IVM practice, but the maturation rate is limited. Biphasic IVM is an improved IVM system proposed in recent years that involves a pre-IVM step using CNP and a subsequent standard IVM step. This can induce meiotic arrest of the oocytes to enhance the communication between oocytes and somatic cells during the pre-IVM stage [26]. The biphasic IVM system has been extensively studied in polycystic ovary syndrome (PCOS) and high AFC populations. Recent studies reported that immature oocytes cultured in the biphasic IVM system can reach a 60% to 70% maturation rate, which is significantly higher than the standard IVM system in those populations, which has been fixed at ∼50% for decades [22, 27, 28]. Biphasic IVM results in a 63.2% clinical pregnancy rate and 50% live birth rate in the PCOS population [28]. To our knowledge, the IVM method used in the published studies of OTO-IVM in FP populations was standard IVM. Only one study used a biphasic IVM system for OTO-IVM in a cohort of 10 gynecological oncology patients, which demonstrated a significant improvement in the IVM rate (reference: 56%) compared with the standard IVM system [29]. However, there are no studies on the use of biphasic IVM for OTO-IVM in hematological patients. Therefore, our study first provided specific outcomes of OTO-biphasic IVM in hematological patients. Our study demonstrated the successful application of a biphasic IVM system for oocyte maturation in hematological patients before HSCT. The results show superior outcomes compared with the limited published data on OTO-IVM in hematological patients [30, 31]. However, the IVM rate and MII oocyte yield were lower than those reported in other populations with PCOS, breast cancer and gynaecologic tumors [27, 29, 32]. Current research suggests that preserving six to eleven oocytes can be expected to reach the maximum live birth rate for women aged younger than 30 years [33], but most patients with non-MHD and MHD are expected to have fewer than five oocytes through OTO-biphasic IVM. Therefore, comprehensive risk disclosure and informed consent acquisition are mandatory prerequisites before the procedure. Further research is needed to find solutions to increase the IVM rate and MII oocyte yield in hematological patients. To our surprise, we found that the ovarian reserve and OTO number were lower in the MHD group, but the IVM rate seemed to be higher than the non-MHD group. Therefore, the final number of MII oocytes was similar in two groups. Notably, AMH is widely regarded as a marker of ovarian reserve reflecting the pool of small antral follicles rather than a direct indicator of oocyte developmental competence [34, 35]. In our cohort, the higher AMH levels observed in the non-MHD group were consistent with the greater number of OTOs retrieved in this group. However, ovarian reserve does not necessarily translate into improved oocyte maturation capacity, which may explain why the non-MHD group exhibited a lower IVM rate despite a higher AMH level. To our knowledge, there is a risk of malignant cell reimplantation during ovarian cortex transplantation in MHD patients, especially in patients with leukaemia. Therefore, performing OTO-IVM in MHD patients to cryopreserve oocytes for future use is clinically meaningful. However, a key concern for patients with MHD is that many have already been exposed to chemotherapy prior to FP. Due to the aggressive nature of diseases such as acute leukemia, life-saving chemotherapy often needs to be initiated immediately after diagnosis, leaving limited opportunity for FP before gonadotoxic treatment. Consequently, FP procedures are frequently performed within a narrow time window between initial chemotherapy exposure and HSCT [36, 37]. Therefore, short-term chemotherapy exposure before OTC is often unavoidable in real-world clinical practice for MHD patients undergoing urgent FP. Chemotherapy agents may potentially harm oocytes and ovarian tissue. Animal studies have suggested that chemotherapeutic agents influence follicle quality, increase the risk of future pregnancy failure, and increase the risk of abnormalities in offsprings, suggesting that human oocyte cryopreservation is recommended 6–12 months after the last chemotherapy [38–40]. However, the 2019 ASRM guidelines proposed that the optimal safe chemotherapy interval is unclear due to a lack of data from human studies [41]. One study reported that successful oocyte maturation was achieved in chemotherapy-exposed patients with OTO-IVM, with corresponding maturation rates of 26.4%, which was lower than our center’s results. In addition, Karavani G et al. reported that chemotherapy exposure was significantly associated with diminished OTO yield in patients with Hodgkin’s lymphoma, whereas no significant effects were observed on maturation rates or the number of mature oocytes obtained [30]. Whether chemotherapy affects mature oocyte yield and oocyte quality in OTO-IVM requires further investigation. A total of 92.31% of patients in our MHD group underwent chemotherapy, but still had a high IVM rate close to 50%. And HE staining revealed no significant abnormalities in follicular morphology, and no obvious apoptosis in ovarian cells was detected in the ovarian tissues of MHD patients subjected to chemotherapy. Hence, we currently assume that OTO-IVM is a valuable protocol for enriching potential reproductive materials for future use and eliminating the risk of tumour cell reimplantation for MHD patients, but the effect of short chemotherapy-free intervals on the reproductive outcomes and off-spring safety using oocytes obtained from OTO-IVM needs further study. As AA is a benign hematologic disorder, the OTO-IVM rate of AA patients is not as high as expected, at only 35.80%. However, it is possible to obtain more than 10 MII oocytes and future use of oocytes is free of chemotherapy-exposure considerations. Hence, OTO-IVM should be considered in patients with AA. However, are there any potential factors leading to impaired maturation competence in patients with AA? Our study demonstrated that increased apoptosis of ovarian stromal cells may account for the compromised oocyte quality in patients with AA. These alterations may affect the ovarian microenvironment and impair oocyte developmental competence even when ovarian reserve, as reflected by AMH levels, appears relatively preserved. Current evidence suggests that AA most often arises from T cell-mediated autoimmune dysregulation, which drives the destruction of hematopoietic stem and progenitor cells and compromises bone marrow microenvironmental function [42–44]. Hypothetically, this autoimmune dysregulation, particularly chronic T-cell activation, may extend to the ovarian niche, inducing oophoritis and disrupting follicular homeostasis. Our RNA-sequencing analyses first substantiated this hypothesis by revealing significant dysregulation of T-cell activation pathways in the ovarian tissues of patients with AA. This finding implies that T-cell activation associated with immune hyperactivity may contribute to ovarian fibrosis and stromal apoptosis, which may alter the ovarian microenvironment and ultimately impair in vitro oocyte maturation capacity. Our study provides the first mechanistic evidence linking AA to ovarian dysfunction, revealing reduced oocyte maturation competence, increased apoptosis of ovarian stromal cells, and potential mechanisms of this pathology. Currently, gonadotropin priming has been explored in several FP studies. However, no strict predefined criteria have been established for its use. In our center, Gn-priming was applied in a small number of patients prior to OTC and OTO-IVM. The decision was made on an individual clinical basis, taking into account the patient’s general condition, the limited time available before HSCT, and the patient’s acceptance of additional hormonal stimulation. However, due to the limited sample size in our cohort, the potential effect of Gn-priming should be interpreted with caution. Previous studies have suggested that short-term gonadotropin priming may improve oocyte yield or maturation outcomes in IVM settings. A large RCT in another centre, which included one arm of OPU biphasic IVM in a high-AFC population, stimulated patients with highly purified hMG 150 IU/day for 2 days. This approach ultimately yielded a 64.3% IVM rate with a 35.2% live birth rate [21]. As for OTO-IVM procedure, Hourvitz et al. reported that gonadotropin priming before OTO-IVM may increase the number of retrieved oocytes and consequently the number of mature oocytes without increasing surgical complications [17]. In addition, recent evidence suggests that gonadotropin priming may improve oocyte maturation rates in premenarcheal girls undergoing OTC [45]. Nevertheless, evidence regarding the optimal indications or ideal dosing strategy for Gn-priming in OTO-IVM remains limited, and further clinical studies are required to establish standardized indications and dosing protocols. This study has several limitations. First, the sample size was relatively small and the study was retrospective in nature, which may limit the statistical power and introduce potential selection bias. Second, prior chemotherapy exposure may represent a potential confounding factor. In our cohort, chemotherapy exposure occurred almost exclusively in patients with malignant hematological diseases, resulting in strong collinearity with disease category and limiting the ability to adjust for chemotherapy-related factors in multivariable analyses. Larger prospective studies with more detailed treatment information, including cumulative dose and regimen type, will be necessary to better explore the independent effects of disease characteristics and chemotherapy exposure on oocyte competence. Additionally, most patients in this cohort underwent fertility preservation before HSCT were relatively young, and many had not yet reached their reproductive stage. As a result, only a limited number of patients have returned to use their cryopreserved oocytes so far, making it difficult to evaluate downstream reproductive outcomes such as fertilization, embryo development, pregnancy, or live birth at this stage. This situation is commonly observed in fertility preservation studies involving oncology or hematological patients. Long-term follow-up of these patients is ongoing, and future studies will further assess fertilization potential, embryo development, and reproductive outcomes using oocytes derived from OTO-IVM. Despite these limitations, our findings support the feasibility of immature oocyte culture using OTO-biphasic IVM in hematological patients before HSCT and provide hypothesis-generating observations regarding factors that may contribute to the lower maturation rate observed in patients with aplastic anemia, which may inform future research. Conclusion OTO-IVM may serve as a feasible urgent FP protocol supplement to OTC in both malignant and benign hematological patients before HSCT to maximise the diversity of reproductive materials. For patients with MHD, the risk of malignant cell reimplantation can be avoided by OTO-IVM, but the effect of chemotherapy exposure on oocyte quality needs to be further established. Although patients with AA maintain preserved AMH levels, their OTO-IVM outcomes reveal compromised oocyte maturation competence. The increased apoptosis of ovarian stromal cells may be the potential reason for the lower maturation rate in patients with AA. Supplementary Information Supplementary Material 1. Supplementary Material 1.